Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2026)

Aquestive Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $19.1 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 3.17% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 3.17% YoY), while the FY2025 annual figure was $19.4 million, down 3.07% from the prior year.
• Non-Current Deffered Revenue was $19.1 million for Q1 2026 at Aquestive Therapeutics, down from $19.4 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $33.1 million in Q2 2023 to a low of $13.5 million in Q2 2022.
• Historically, Non-Current Deffered Revenue has averaged $23.5 million across 5 years, with a median of $20.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue jumped 341.13% in 2022, then sank 38.22% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $31.4 million in 2022, then grew by 2.95% to $32.3 million in 2023, then sank by 38.15% to $20.0 million in 2024, then slipped by 3.07% to $19.4 million in 2025, then fell by 1.4% to $19.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $19.1 million (Q1 2026), $19.4 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.